

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-11 (cancelled)

12. (new) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation.

13. (new) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation according to claim 12 characterised in that vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage.

14. (new) Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation according to claim 12 characterised in that vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage, including those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.

15. (new) Use of HMG box binding molecules according to claim 12 wherein said molecules belong to the group comprising

antibodies or antibodies fragments, inhibitors and four-way DNA.

16. (new) Therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation characterised in that it comprises a therapeutic active amount of HMG box binding molecules.

17. (new) Therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation according to claim 16 wherein said molecules belong to the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA and not sRAGE.

18. (new) Therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation characterised in that it comprises a therapeutic active amount of antagonist molecules having sequence homology with HMG box and being able to bind the functional HMG box binding domain of the receptor.

19. (new) Therapeutic agent according to claim 16 characterised in that it is released by catheters, surgical instruments implants or stents.